{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T16:58:38Z","timestamp":1792083518854,"version":"4.4.0"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":1616,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2021,7,6]],"date-time":"2021-07-06T00:00:00Z","timestamp":1625529600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Information regarding adverse events (AEs) of mycophenolate mofetil (MMF) is limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate the types and frequency of potential AEs of MMF in dogs with immune-mediated disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Animals<\/jats:title>\n                    <jats:p>One hundred thirty-one dogs treated with MMF for management of suspected immune-mediated disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Retrospective study. Medical records were reviewed to find and group suspect AEs in gastrointestinal (GI), hematologic, and other categories. Age, dosage, body weight, and sex were analyzed between dogs with and without AEs by using the Mann-Whitney U-test and chi-squared test.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The median starting dosage of MMF was 17.5\u2009mg\/kg\/day (interquartile range [IQR]\u00a0=\u00a015.1-20.6\u2009mg\/kg\/day) and the median treatment duration was 56\u2009days (IQR\u00a0=\u00a014-236\u2009days). Mycophenolate mofetil was prescribed for immune-mediated hemolytic anemia (n\u00a0=\u00a031), immune-mediated thrombocytopenia (n\u00a0=\u00a031), pemphigus foliaceus (n\u00a0=\u00a015), immune-mediated polyarthritis (n\u00a0=\u00a012), and others (n\u00a0=\u00a042). Overall, potential AEs of MMF were observed in 34 of 131 dogs (GI 24.4% [31\/127], neutropenia 4% [3\/76], anemia 4% [1\/25], thrombocytopenia 4.0% [1\/25], and dermatologic 1.5% [2\/131]). There were no significant differences among dogs with (n\u00a0=\u00a037) or without potential AEs (n\u00a0=\u00a094) in regards to sex, age, body weight, or dosage of MMF (P\u00a0=\u2009.06, .13, .24, and .26, respectively).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and Clinical Importance<\/jats:title>\n                    <jats:p>In the dogs administered MMF, GI AEs were most common. Since potential hematologic and dermatologic AEs developed in a few dogs, clinicians should be aware of these when prescribing MMF to dogs with immune-mediated disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jvim.16209","type":"journal-article","created":{"date-parts":[[2021,7,6]],"date-time":"2021-07-06T22:54:20Z","timestamp":1625612060000},"page":"2215-2221","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["A retrospective study of adverse effects of mycophenolate mofetil administration to dogs with immune-mediated disease"],"prefix":"10.1093","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4271-8267","authenticated-orcid":false,"given":"Kenjiro","family":"Fukushima","sequence":"first","affiliation":[{"name":"Colorado State University Department of Clinical Sciences, , Fort Collins, Colorado,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1605-9667","authenticated-orcid":false,"given":"Michael","family":"Lappin","sequence":"additional","affiliation":[{"name":"Colorado State University Department of Clinical Sciences, , Fort Collins, Colorado,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Legare","sequence":"additional","affiliation":[{"name":"Colorado State University Department of Environmental and Radiological Health Science, , Fort Collins, Colorado,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Veir","sequence":"additional","affiliation":[{"name":"Colorado State University Department of Clinical Sciences, , Fort Collins, Colorado,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,9,1]]},"reference":[{"key":"2026020303471182100_jvim16209-bib-0001","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/jvp.12731","article-title":"Mycophenolic acid in patients with immune-mediated inflammatory diseases: from humans to dogs","volume":"42","author":"Klotsman","year":"2019","journal-title":"J Vet Pharmacol Ther"},{"key":"2026020303471182100_jvim16209-bib-0002","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/jsap.12107","article-title":"Treatment of canine idiopathic immune-mediated haemolytic anaemia with mycophenolate mofetil and glucocorticoids: 30 cases (2007 to 2011)","volume":"54","author":"Wang","year":"2013","journal-title":"J Small Anim Pract"},{"key":"2026020303471182100_jvim16209-bib-0003","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/vec.12121","article-title":"Treatment of idiopathic immune-mediated hemolytic anemia with mycophenolate mofetil in five dogs","volume":"24","author":"West","year":"2014","journal-title":"J Vet Emerg Crit Care"},{"key":"2026020303471182100_jvim16209-bib-0004","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/jsap.12203","article-title":"Treatment of five haemodynamically stable dogs with immune-mediated thrombocytopenia using mycophenolate mofetil as single agent","volume":"55","author":"Yau","year":"2014","journal-title":"J Small Anim Pract"},{"key":"2026020303471182100_jvim16209-bib-0005","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/jsap.12621","article-title":"Treatment of presumptive primary immune-mediated thrombocytopenia with mycophenolate mofetil versus cyclosporine in dogs","volume":"58","author":"Cummings","year":"2017","journal-title":"J Small Anim Pract"},{"key":"2026020303471182100_jvim16209-bib-0006","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/vde.12400","article-title":"Use of mycophenolate mofetil to treat immune-mediated skin disease in 14 dogs \u2013 a retrospective evaluation","volume":"28","author":"Ackermann","year":"2017","journal-title":"Vet Dermatol"},{"key":"2026020303471182100_jvim16209-bib-0007","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/vms3.22","article-title":"Treatment of canine meningoencephalomyelitis of unknown aetiology with mycophenolate mofetil and corticosteroids: 25 cases (2007\u20132012)","volume":"2","author":"Woolcock","year":"2016","journal-title":"Vet Med Sci"},{"key":"2026020303471182100_jvim16209-bib-0008","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1111\/jvim.12228","article-title":"Consensus recommendations for immunosuppressive treatment of dogs with glomerular disease based on established pathology","volume":"27","author":"IRIS Canine GN Study Group Established Pathology Subgroup","year":"2013","journal-title":"J Vet Intern Med"},{"key":"2026020303471182100_jvim16209-bib-0009","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/sj.bmt.1705958","article-title":"Pharmacokinetics of oral mycophenolate mofetil in combination with CsA in dogs after nonmyeloablative allogeneic hematopoietic stem cell transplantation","volume":"41","author":"Lange","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"2026020303471182100_jvim16209-bib-0010","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/vop.12545","article-title":"Clinical therapeutic efficacy of mycophenolate mofetil in the treatment of SARDS in dogs-a prospective open-label pilot study","volume":"21","author":"Young","year":"2018","journal-title":"Vet Ophthalmol"},{"key":"2026020303471182100_jvim16209-bib-0011","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1002\/jcph.1428","article-title":"Influence of calcineurin inhibitor and sex on mycophenolic acid pharmacokinetics and adverse effects post-renal transplant","volume":"59","author":"Meaney","year":"2019","journal-title":"J Clin Pharmacol"},{"key":"2026020303471182100_jvim16209-bib-0012","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/jvim.15441","article-title":"ACVIM consensus statement on the diagnosis of immune-mediated hemolytic anemia in dogs and cats","volume":"33","author":"Garden","year":"2019","journal-title":"J Vet Intern Med"},{"key":"2026020303471182100_jvim16209-bib-0013","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/jsap.12912","article-title":"Long-term outcome of primary immune-mediated thrombocytopenia in dogs","volume":"59","author":"Simpson","year":"2018","journal-title":"J Small Anim Pract"},{"key":"2026020303471182100_jvim16209-bib-0014","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/vde.12143","article-title":"Serum autoantibody profiles of IgA, IgE and IgM in canine pemphigus foliaceus","volume":"25","author":"Bizikova","year":"2014","journal-title":"Vet Dermatol"},{"key":"2026020303471182100_jvim16209-bib-0015","doi-asserted-by":"crossref","first-page":"312","DOI":"10.2460\/javma.236.3.312","article-title":"Efficacy of leflunomide for treatment of immune-mediated polyarthritis in dogs: 14 cases (2006-2008)","volume":"236","author":"Colopy","year":"2010","journal-title":"J Am Vet Med Assoc"},{"key":"2026020303471182100_jvim16209-bib-0016","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1124\/dmd.104.001651","article-title":"Identification of the UDP-glucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism","volume":"33","author":"Picard","year":"2005","journal-title":"Drug Metab Dispos"},{"key":"2026020303471182100_jvim16209-bib-0017","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.transproceed.2006.10.189","article-title":"Noninfectious gastrointestinal (GI) complications of mycophenolic acid therapy: a consequence of local GI toxicity?","volume":"39","author":"Arns","year":"2007","journal-title":"Transplant Proc"},{"key":"2026020303471182100_jvim16209-bib-0018","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aax2358","article-title":"Vancomycin relieves mycophenolate mofetil\u2013induced gastrointestinal toxicity by eliminating gut bacterial -glucuronidase activity","volume":"5","author":"Taylor","year":"2019","journal-title":"Sci Adv"},{"issue":"5","key":"2026020303471182100_jvim16209-bib-0019","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/j.transproceed.2005.02.038","article-title":"Mycophenolate mofetil \u2013 induced neutropenia in liver transplantation","volume":"37","author":"Nogueras","year":"2005","journal-title":"Transplant Proc"},{"key":"2026020303471182100_jvim16209-bib-0020","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1111\/apt.15157","article-title":"Systematic review with meta-analysis: mycophenolate mofetil as a second-line therapy for autoimmune hepatitis","volume":"49","author":"Santiago","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"2026020303471182100_jvim16209-bib-0021","doi-asserted-by":"crossref","first-page":"119","DOI":"10.5414\/CNP60119","article-title":"Four cases of red blood cell aplasia in association with the use of mycophenolate mofetil in renal transplant patients","volume":"60","author":"Engelen","year":"2003","journal-title":"Clin. Nephrol"},{"key":"2026020303471182100_jvim16209-bib-0022","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1097\/TP.0b013e318238da98","article-title":"A possible explanation for anemia in patients treated with mecophenolic acid","volume":"92","author":"Pile","year":"2011","journal-title":"Transplantation"},{"key":"2026020303471182100_jvim16209-bib-0023","first-page":"40","article-title":"Safety of mycophenolate mofetil monotherapy in patients after liver transplantation","volume":"14","author":"Kamphues","year":"2009","journal-title":"Ann Transplant"},{"key":"2026020303471182100_jvim16209-bib-0024","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1111\/j.1939-1676.2012.00927.x","article-title":"Drug hypersensitivity reactions targeting the skin in dogs and cats","volume":"26","author":"Voie","year":"2012","journal-title":"J Vet Intern Med"},{"key":"2026020303471182100_jvim16209-bib-0025","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/01.wnf.0000167361.35294.da","article-title":"Severe skin reaction related to mycophenolate mofetil for myasthenia gravis","volume":"28","author":"Levin","year":"2005","journal-title":"Clin Neuropharmacol"},{"key":"2026020303471182100_jvim16209-bib-0026","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/00007890-199601150-00018","article-title":"Pharmacodynamic assessment of mycophenolic acid-induced immunosuppression by measurement of inosine monophosphate dehydrogenase activity in a canine model","volume":"61","author":"Langman","year":"1996","journal-title":"Transplantation"}],"updated-by":[{"DOI":"10.1111\/jvim.16493","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2022,7,20]],"date-time":"2022-07-20T00:00:00Z","timestamp":1658275200000}}],"container-title":["Journal of Veterinary Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvim.16209","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jvim.16209","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/35\/5\/2215\/66672929\/jvim16209.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/35\/5\/2215\/66672929\/jvim16209.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T08:47:30Z","timestamp":1770108450000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jvim\/article\/35\/5\/2215\/8448551"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,1]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,9,1]]}},"URL":"https:\/\/doi.org\/10.1111\/jvim.16209","relation":{},"ISSN":["1939-1676"],"issn-type":[{"value":"1939-1676","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,9]]},"published":{"date-parts":[[2021,9,1]]},"assertion":[{"value":"2020-06-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-18","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-06","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}